Quarterly ResultAug 3, 2026, 04:05 PM
Inspire Medical Q2 Revenue $200.6M; EPS $0.01; Announces $30M Growth Plan
AI Summary
Inspire Medical Systems reported Q2 2026 financial results, with revenue of $200.6 million and diluted EPS of $0.01, or $0.14 adjusted. The company also announced a strategic growth plan, 'Project Horizon,' designed to generate $30 million in annualized growth investment capacity for targeted initiatives. Despite a 7.6% decrease in Q2 revenue year-over-year, primarily due to U.S. reimbursement changes, gross margin improved to 85.5% and operating cash flow was $23.2 million. Inspire raised its full-year 2026 revenue outlook to $835 million-$875 million and adjusted operating margin to 4%-6%.
Key Highlights
- Announced strategic growth plan 'Project Horizon' to unlock $30 million for growth initiatives.
- Q2 2026 revenue was $200.6 million, a 7.6% decrease from Q2 2025.
- Q2 2026 diluted EPS was $0.01; adjusted diluted EPS was $0.14.
- Gross margin increased 150 bps to 85.5% in Q2 2026.
- Operating cash flow for Q2 2026 was $23.2 million.
- Raised full-year 2026 revenue guidance to $835 million to $875 million.
- Expects full-year 2026 adjusted operating margin of 4% to 6%.
- Anticipates $20 million to $25 million pre-tax restructuring charges for Project Horizon.
Price Impact
More from INSP